Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | DESTINY-Lung01: cohort expansion results

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the cohort expansion results from the Phase Ib DESTINY-Lung01 trial (NCT03505710), presented by Dr Bob Li at ESMO 2021, which looked at trastuzumab deruxtecan for patients with HER2 mutant non-small cell lung cancer (NSCLC). Overall response rate was 55%, median progression-free survival was 8.2 months, and the median overall survival was 17.8 months, with nearly all patients having tumour shrinkage. Prof. Popat highlights how encouraging these trial results are for patients with NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.